Employees: 2,257
Size JIANMIN PHARMACEUTICAL (600976.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $598M, the 3250th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.39 on 18 Nov 2026.
Performance Over six months the shares fell 14.2%, against -31.3% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 1.7% over the last twelve months (peer median +2.9%); the operating margin is 8.1% (peer median 2.2%).
Valuation It trades at 6.7× forward earnings against a peer median of 26.8× (2nd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.7 points above its cost of capital (6.8% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.12B | CN¥3.35B | CN¥3.48B | CN¥4.18B | CN¥3.62B |
| Revenue growth | — | -4% | -17% | +16% | — |
| Gross profit | CN¥1.86B | CN¥1.91B | CN¥1.61B | CN¥1.88B | CN¥1.52B |
| EBITDA | n/a | CN¥302M | CN¥181M | CN¥372M | CN¥300M |
| Net income | CN¥312M | CN¥360M | CN¥362M | CN¥521M | CN¥408M |
| Free cash flow | CN¥418M | CN¥174M | CN¥311M | CN¥307M | CN¥323M |
| Capital expenditure | CN¥104M | CN¥101M | CN¥120M | CN¥64.5M | CN¥68.0M |
| Total debt | CN¥245M | CN¥292M | CN¥397M | CN¥501M | CN¥367M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600976.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.9% | -11.8% | 6th highest of 20 |
| 6-month return | -14.2% | -31.3% | 6th highest of 20 |
| Distance from 52-week high | -34.5% | -44.1% | 4th highest of 20 |
| Revenue growth (TTM) | -1.7% | +2.9% | 7th lowest of 16 |
| Operating margin | 8.1% | 2.2% | 3rd highest of 15 |
| Forward P/E | 6.7× | 26.8× | 2nd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | -6.2% | 9.1% | 3rd least demanding of 10 |
| Growth delivered (Del g) | +6.5% | -1.6% | 3rd highest of 10 |
| Hurdle (Req g minus delivered) | -12.7 pp | +8.1 pp | 2nd least demanding of 10 |
| ROIC minus cost of capital | +7.7 pp | -5.4 pp | 2nd highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 11.4× | -6.6% | +5.4% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | n/a | -1.0% | -17.9% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 26.8× | 20.9% | +21.9% |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | n/a | n/a | n/a |